S. Blau

发表

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology

G. Lyman, C. A. Blau, N. Kuderer, 2017, JAMA oncology.

Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies

William Stafford Noble, John T. Halloran, J. Bilmes, 2017, bioRxiv.

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

B. Kermani, E. Collisson, S. Mortimer, 2015, PloS one.

Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer

G. Lyman, C. A. Blau, D. Veenstra, 2017, JCO precision oncology.

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

P. Lønning, T. Decker, A. Leo, 2017 .

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients

G. Dranitsaris, S. Blau, M. Moezi, 2022, Supportive Care in Cancer.

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

P. Lønning, S. Johnston, T. Decker, 2018, The Lancet. Oncology.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Secret Sauce-How Diverse Practices Succeed in Centers for Medicare & Medicaid Services Oncology Care Model.

S. Blau, J. R. Hoverman, G. Rocque, 2021, JCO oncology practice.

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients

G. Dranitsaris, S. Blau, M. Moezi, 2022, Supportive Care in Cancer.

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

H. Burris, D. Yardley, G. Jerusalem, 2018 .

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

Altered T cell subpopulations and lymphocytes expressing natural killer cell phenotypes in patients with progressive systemic sclerosis.

C. Mele, S. Blau, M. Frieri, 1991, The Journal of allergy and clinical immunology.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2016, The New England journal of medicine.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

M. Espié, Sung-Bae Kim, J. Baselga, 2017, The Lancet. Oncology.

Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies

William Stafford Noble, Jie Liu, Jay Shendure, 2017, Scientific Reports.

A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.

Chris P. Miller, D. Haussler, Su-In Lee, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

COVID-19 vaccination and breakthrough infections in patients with cancer

Y. Shyr, E. Wulff-Burchfield, C. Friese, 2021, Annals of Oncology.

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

T. Choueiri, Y. Shyr, R. Nanchal, 2023, The Lancet Regional Health - Americas.

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

M. Dorschner, Janusz Dutkowski, B. Mecham, 2022, JCO precision oncology.

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Anand A. Dalal, G. Hortobagyi, B. Ramaswamy, 2019, Clinical breast cancer.

Cis-Compound Mutations are Prevalent in Triple Negative Breast Cancer and Can Drive Tumor Progression

William Stafford Noble, W. L. Ruzzo, D. Haussler, 2016, bioRxiv.

High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining

A. Breman, M. Dorschner, B. Friemel, 2015, BMC Cancer.

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

P. Fasching, E. Winer, P. V. van Dam, 2019, Clinical Cancer Research.

Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

I. Makhoul, A. Bardia, K. Wisinski, 2020 .

Telehealth in Oncology: ASCO Standards and Practice Recommendations

D. Patt, R. Zon, T. Mulvey, 2021, JCO oncology practice.

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Jonathan M Marron, Laura A. Levit, R. Schilsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

H. Burris, D. Yardley, G. Jerusalem, 2018, JAMA oncology.

Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

M. Galsky, J. Riess, M. Robson, 2023, medRxiv.

Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting

A. Gajra, S. Blau, John W. Showalter, 2021, JCO oncology practice.

Augmented intelligence to predict 30-day mortality in patients with cancer.

A. Gajra, S. Blau, John W. Showalter, 2021, Future oncology.

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.

A. Bardia, A. DeMichele, L. Hart, 2019, Journal of Clinical Oncology.

Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2

G. Hortobagyi, M. Campone, L. Hart, 2018 .

Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics

G. Hortobagyi, F. André, M. Campone, 2016 .

139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)

M. Espié, A. Tan, S. Im, 2020 .

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.

M. Cooney, S. Blau, S. Damodaran, 2022, JCO clinical cancer informatics.

Reducing Cancer Costs Through Symptom Management and Triage Pathways.

M. Soobader, S. Blau, R. Page, 2019, Journal of Oncology Practice.

Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

A. Bardia, H. Rugo, A. DeMichele, 2021, Clinical Cancer Research.

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

G. Hortobagyi, F. André, M. Campone, 2017 .

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

P. Neven, H. Rugo, L. Hart, 2023, Breast Cancer Research.

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

G. Dranitsaris, S. Blau, C. Faria, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

P. Stephens, V. Miller, R. Erlich, 2017, Clinical breast cancer.

Access to Cancer Care – The Perspective of an Independent Community Oncologist

S. Blau, 2022, International Journal of Cancer Care and Delivery.

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

M. Espié, Sung-Bae Kim, J. Baselga, 2018 .

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

M. Campone, H. Burris, J. Beck, 2018 .